BUY Punjab National Bank

All-round strong performance; upgrade to BUY

BFSI - Banks > Result Update > January 26, 2024

PNB continued to report a strong beat on PAT at Rs22bn (Emkay est.: Rs19.2bn) mainly due to contained staff cost despite wage hike provision and lower provisions due to reversal of NPI provisions on one lumpy corporate. Amid margin pressure across banks, PNB once again reported a 4bps QoQ margin expansion to 3.15% due to better LDR and interest recognition on lumpy NPA recoveries. Asset quality continued to improve, with fresh slippage run-rate now at a decadal low of 0.9% and NNPA at ~1% of loans, which should lead to a sharp reduction in LLP. The bank still operates on the old-tax regime and migration to the new regime could boost profitability. Factoring in a better margin trajectory and asset-quality improvement and migration to the new tax regime over FY25-26, we raise our FY24E/FY25/FY26E earnings estimates by 15-40% and expect the bank to deliver 0.5-1% RoA/8-14% RoE. Thus, we revise our TP to Rs125/share (vs. Rs78), based on 1x its Dec-25E ABV and subsidiary's value at Rs11/share. We upgrade the stock to BUY from Reduce.

Y/E March (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Net profit	34,570	25,072	76,373	135,825	178,357
Loan growth (%)	8.0	14.1	14.1	14.0	15.5
NII growth (%)	(6.1)	20.2	16.8	8.9	10.2
NIM (%)	2.5	2.7	2.9	2.8	2.8
PPOP growth (%)	(6.3)	8.5	10.8	6.1	16.8
Adj. EPS (Rs)	3.2	2.3	6.9	12.0	15.3
Adj. EPS growth (%)	37.0	(29.2)	204.6	72.6	27.6
Adj. BV (INR)	55.0	66.3	81.8	93.6	107.9
Adj. BVPS growth (%)	8.4	20.6	23.3	14.5	15.3
RoA (%)	0.3	0.2	0.5	0.8	1.0
RoE (%)	4.0	2.8	8.1	12.7	14.3
P/E (x)	29.2	41.3	13.5	7.8	6.2
P/ABV (x)	1.7	1.4	1.1	1.0	0.9

Source: Company, Emkay Research

Margins continue to ascend amid pressure seen across other banks

Credit growth remained healthy at 14.5% YoY/3% QoQ with continued focus on the RAM segment (which constitutes 56% of the total net advances), while deposit growth remained consciously low at 9% YoY/1% QoQ, leading to steady improvement in LDR to 69%. This coupled with interest recognition on recovered NPAs led to a 4bps QoQ increase in NIM to 3.15%, amid most other banks experiencing margin pressure. Going forward, the bank plans to further expand its LDR, which we believe should continue to support margins for the bank in the near-medium term.

Slippages at a decadal low and so also NNPA at $\sim 1\%$

Fresh slippages continued to decelerate at Rs17.9bn/0.9% of loans, which coupled with higher recovery/write-offs, led to a 72bps QoQ dip in the GNPA ratio to 6.2%. Specific PCR further improved to 85%, which led to a 51bps reduction in NNPA to a decadal low of ~1%. The restructured pool also stands reduced to 1% of loans, which is relatively lower vs. some other PSBs. The bank recovered NPAs worth ~Rs29bn from NCLT during 9MFY24 and expects further recoveries of Rs12bn in Q4FY24. According to management's guidance, the bank is expected to reach exit RoA of 1% by 4QFY25, led by strong NII/other income and lower LLP.

Upgrade to BUY

Factoring in better margin trajectory, asset-quality improvement, and migration to the new tax regime in FY26, we raise our FY24E/FY25/FY26E earnings estimates by 15-40% and expect PNB to post 0.5-1% RoA/8-14% RoE. Thus, we revise our TP to Rs125/share (vs. Rs78), based on 1x its Dec-25E ABV and the subsidiary's value at Rs11/share. We upgrade the stock to BUY from Reduce. With CET-1 at 10.6%, including 9MFY24 profit, the bank plans to raise capital worth Rs70bn via QIP, which we have built into our FY25 estimates. **Key risks**: Macro deterioration derailing growth/asset-quality normalization.



TARGET PRICE (Rs): 125

Target Price – 12M	Dec-24
Change in TP (%)	NA
Current Reco.	BUY
Previous Reco.	REDUCE
Upside/(Downside) (%)	19.6
CMP (25-Jan-24) (Rs)	104.5
Stock Data	Ticker
52-week High (Rs)	108
52-week Low (Rs)	44
Shares outstanding (mn)	11,011.0
Market-cap (Rs bn)	1,151
Market-cap (USD mn)	13,844
Net-debt, FY24E (Rs mn)	NA
ADTV-3M (mn shares)	59
ADTV-3M (Rs mn)	5,127.5
ADTV-3M (USD mn)	61.7
Free float (%)	27.0
Nifty-50	21,353
INR/USD	83.1
Shareholding, Dec-23	
Promoters (%)	73.2
FPIs/MFs (%)	3.1/13.7

Price Performance								
(%)	1M	3M	12M					
Absolute	17.1	50.4	94.6					
Rel. to Nifty	17.1	34.7	63.1					



Anand Dama

anand.dama@emkayglobal.com +91 22 6624 2480

Kunaal N

kunaal.n@emkayglobal.com +91 22 6612 1275


Marazbaan Dastur

marazbaan.dastur@emkayglobal.com +91 22 6612 1281

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 04/26/2024 02:13 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAYsGO>Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.


Story in Charts

Exhibit 1: Credit growth continues to outpace deposit growth




Source: Company, Emkay Research

Exhibit 3: Domestic CASA remains healthy at 42%




Source: Company, Emkay Research

Exhibit 5: NNPA improved to a decadal low of ~1%




Source: Company, Emkay Research

Exhibit 7: PNB is reasonably valued vs. peers



Source: Bloomberg, Emkay Research

Exhibit 2: NIMs improve due to better LDR and interest recognition on NPA recovery




Source: Company, Emkay Research

Exhibit 4: Slippages were contained at 0.9% of loans, one of the lowest in the decade




Source: Company, Emkay Research

Exhibit 6: We expect the bank to report a gradual improvement in return ratios going forward



Source: Company, Emkay Research

Exhibit 8: The stock currently trades at 0.8x its 1-year forward ABV



Source: Company, Bloomberg, Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 04/26/2024 02:13 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore. Emkay Resear research report or research

Exhibit 9: Actuals vs. Estimates (Q3FY24)

(Rs mn)	Actuals	Estimates		Variation		Variation		Comments
		Emkay	Consensus	Emkay	Consensus			
Net income	129,666	134,409	124,459	-4%	4%	Lower other income led to a miss		
PPOP	63,307	61,991	62,017	2%	2%	Lower staff and operating expenses led to a beat		
PAT	22,228	19,169	16,195	16%	37%	Higher PPOP and contained provisions led to a beat		

Source: Company, Emkay Research

Exhibit 10: Quarterly Summary

(Rs mn)	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	YoY (%)	QoQ (%)	FY23	FY24E	YoY (%)
Interest Earned	223,844	238,486	251,455	263,549	272,878	22	4	851,441	1,072,026	26
Interest Exp.	132,051	143,499	156,412	164,320	169,950	29	3	506,525	669,000	32
Net Interest Income	91,794	94,988	95,043	99,229	102,928	12	4	344,916	403,026	17
Global NIM (reported)	3.16	3.24	3.08	3.11	3.15	-1bps	4bps	2.70	2.85	15bps
Non-interest Income	33,380	34,203	34,338	30,283	26,738	-20	-12	121,425	118,945	-2
Operating Expenses	68,014	70,527	69,701	67,348	66,359	-2	-1	241,054	272,453	13
Pre-Provisioning Profit	57,159	58,664	59,680	62,164	63,307	11	2	225,288	249,519	11
Provision and Contingencies	47,133	38,306	39,653	34,442	27,391	-42	-20	182,405	128,291	-30
PBT	10,026	20,359	20,027	27,723	35,916	258	30	42,883	121,228	183
Income Tax Expense (Gain)	3,737	8,772	7,473	10,161	13,688	266	35	17,811	44,854	152
Net Profit/(Loss)	6,289	11,586	12,554	17,561	22,228	253	27	25,072	76,373	205
Gross NPA (%)	9.76	8.73	7.73	6.96	6.24	-352bps	-72bps	8.73	5.74	-300bps
Net NPA (%)	3.29	2.72	1.98	1.47	0.96	-233bps	-51bps	2.72	0.90	-181bps
Deposits (Rs bn)	12,104	12,812	12,979	13,099	13,235	9	1	12,812	13,742	7
Net Advances (Rs bn)	8,004	8,308	8,637	8,899	9,164	14	3	8,308	9,477	14

Source: Company, Emkay Research

Exhibit 11: Revision in Estimates

Y/E March (Rs mn)	FY24E			FY25E			FY26E		
	Earlier	Revised	Change	Earlier	Revised	Change	Earlier	Revised	Change
Net income	524,852	521,972	-0.5%	551,388	561,952	1.9%	601,937	630,678	4.8%
PPOP	241,332	249,519	3.4%	241,307	264,852	9.8%	265,406	309,329	16.5%
PAT	66,337	76,373	15.1%	97,372	135,825	39.5%	123,014	178,357	45.0%
EPS (Rs)	6.0	6.9	15.1%	8.8	12.0	35.4%	11.2	15.3	36.7%
BV (Rs)	87.8	88.9	1.3%	94.9	100.0	5.4%	103.8	113.3	9.1%

Source: Emkay Research

(%)	FY23A	FY24E	FY25E	FY26E
Loan Growth	14.1	14.1	14.0	15.5
Deposit Growth	11.8	7.3	9.1	11.7
NIM	2.7	2.9	2.8	2.8
GNPA	8.7	5.7	3.9	2.5
Credit Cost	2.1	1.5	0.6	0.7

Source: Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 04/26/2024 02:13 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 13: Key Ratios and Trends

	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24
Loans (Rs bn)	7,562	7,857	8,011	8,311	8,568	8,856	9,175	9,417	9,673
Growth % (YoY)	4.0	6.3	10.3	12.8	13.3	12.7	14.5	13.3	12.9
Growth % (QoQ)	2.7	3.9	2.0	3.7	3.1	3.4	3.6	2.6	2.7
Liability Profile									
Deposits (Rs bn)	11,273	11,462	11,367	11,935	12,104	12,812	12,979	13,099	13,235
growth (YoY)	4.2	3.6	3.6	7.0	7.4	11.8	14.2	9.8	9.3
growth (QoQ)	1.1	1.7	(0.8)	5.0	1.4	5.8	1.3	0.9	1.0
Asset Quality and Capital									
GNPA (%)	12.9	11.8	11.3	10.5	9.8	8.7	7.7	7.0	6.2
NNPA (%)	4.5	4.4	4.0	3.5	3.1	2.6	1.9	1.4	0.9
PCR (%)	65.2	62.2	64.8	66.3	68.5	70.8	75.8	80.0	85.4
Slippages (Rs mn)	44,070	105,060	64,680	59,790	40,720	39,960	23,900	18,260	17,930
Slippages (%)	2.4	5.7	3.6	3.2	2.2	2.0	1.2	0.9	0.8
CAR (%)	14.9	14.5	14.8	14.7	15.2	15.5	15.5	15.1	14.6
Tier I (%)	12.2	11.7	12.1	12.2	12.2	12.7	12.3	12.0	11.7
ROE Decomposition (on total assets; %)									
NII	2.4	2.2	2.3	2.5	2.6	2.7	2.6	2.7	2.7
Other Income (Ex. Treasury)	0.6	0.6	0.6	0.8	0.9	0.9	0.8	0.8	0.6
Treasury	0.2	0.1	0.2	0.0	0.0	0.1	0.1	0.0	0.1
Opex	1.7	1.4	1.4	1.6	2.0	2.0	1.9	1.8	1.8
PPOP	1.6	1.6	1.6	1.7	1.6	1.6	1.6	1.7	1.7
Provisioning Cost	1.0	1.5	1.5	1.5	1.4	1.1	1.1	0.9	0.7
РВТ	0.5	0.1	0.2	0.2	0.3	0.6	0.5	0.7	1.0
Tax	0.2	0.1	0.1	0.1	0.1	0.2	0.2	0.3	0.4
ROA	0.4	0.1	0.1	0.1	0.2	0.3	0.3	0.5	0.6
ROE	4.7	0.8	1.3	1.7	2.5	4.7	5.0	6.9	8.5

Source: Company, Emkay Research

This report is intended for team emkay@whitemarquesolutions com use and downloaded at 04/26/2024 02:13 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Punjab National Bank: Standalone Financials and Valuations

Profit and Loss					
Y/E March (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Interest Income	748,795	851,441	1,072,026	1,150,247	1,242,019
Interest Expense	461,851	506,525	669,000	711,193	758,246
Net interest income	286,945	344,916	403,026	439,054	483,773
NII growth (%)	(6.1)	20.2	16.8	8.9	10.2
Other income	123,200	121,425	118,945	122,897	146,905
Total Income	410,144	466,342	521,972	561,952	630,678
Operating expenses	202,526	241,054	272,453	297,100	321,349
РРОР	207,618	225,288	249,519	264,852	309,329
PPOP growth (%)	(6.3)	8.5	10.8	6.1	16.8
Core PPOP	178,267	236,659	243,238	247,895	275,416
Provisions & contingencies	164,454	182,405	128,291	62,128	71,520
PBT	43,164	42,883	121,228	202,724	237,809
Extraordinary items	0	0	0	0	(
Tax expense	8,594	17,811	44,854	66,899	59,452
Minority interest	0	0	0	0	C
Income from JV/Associates	0	0	0	0	C
Reported PAT	34,570	25,072	76,373	135,825	178,357
PAT growth (%)	71.0	(27.5)	204.6	77.8	31.3
Adjusted PAT	34,570	25,072	76,373	135,825	178,357
Diluted EPS (Rs)	3.2	2.2	6.8	11.8	15.0
Diluted EPS growth (%)	51.9	(29.2)	204.6	72.7	27.6
DPS (Rs)	0.7	0.7	1.0	1.5	2.0
Dividend payout (%)	20.4	28.5	14.4	12.9	13.1
Effective tax rate (%)	19.9	41.5	37.0	33.0	25.0
Net interest margins (%)	2.5	2.7	2.9	2.8	2.8
Cost-income ratio (%)	49.4	51.7	52.2	52.9	51.0
Shares outstanding (mn)	11,011.0	11,011.0	11,011.0	11,677.7	11,677.7

Balance Sheet					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Share capital	22,022	22,022	22,022	23,355	23,355
Reserves & surplus	932,847	976,535	1,041,509	1,228,137	1,382,738
Net worth	954,869	998,557	1,063,531	1,251,492	1,406,093
Deposits	11,462,184	12,811,631	13,742,067	14,996,776	16,748,238
Borrowings	456,814	512,917	606,459	670,775	745,955
Interest bearing liab.	11,918,999	13,324,548	14,348,526	15,667,551	17,494,193
Other liabilities & prov.	274,183	295,209	169,700	229,803	435,983
Total liabilities & equity	13,148,050	14,618,314	15,581,757	17,148,846	19,336,269
Net advances	7,281,857	8,308,340	9,476,935	10,799,407	12,470,045
Investments	3,721,678	3,959,967	4,214,554	4,310,393	4,623,863
Cash, other balances	1,326,468	1,551,088	1,074,397	1,166,729	1,294,594
Interest earning assets	12,330,002	13,819,395	14,765,886	16.276.528	18,388,501
Fixed assets	106,736	120,511	129,208	142,129	156,342
Other assets	711,312	678,408	686,663	730,189	791,426
Total assets					
B) (BQ (B)	13,148,050	14,618,314	15,581,757	17,148,846	19,336,269
BVPS (Rs)	13,148,050 80.3	14,618,314 83.0	15,581,757 88.9	17,148,846 100.0	
Adj. BVPS (Rs)					113.3
	80.3	83.0	88.9 83.1	100.0	113.3 109.3
Adj. BVPS (Rs)	80.3 56.3	83.0 67.7	88.9 83.1	100.0 94.9	113.3 109.3 12,720,422
Adj. BVPS (Rs) Gross advances	80.3 56.3 7,853,575	83.0 67.7 8,855,766	88.9 83.1 9,962,736	100.0 94.9 11,158,265	113.3 109.3 12,720,422 74.5
Adj. BVPS (Rs) Gross advances Credit to deposit (%)	80.3 56.3 7,853,575 63.5	83.0 67.7 8,855,766 64.8	88.9 83.1 9,962,736 69.0	100.0 94.9 11,158,265 72.0	113.3 109.3 12,720,422 74.5 42.0
Adj. BVPS (Rs) Gross advances Credit to deposit (%) CASA ratio (%)	80.3 56.3 7,853,575 63.5 46.6	83.0 67.7 8,855,766 64.8 42.0	88.9 83.1 9,962,736 69.0 41.1 4.7	100.0 94.9 11,158,265 72.0 41.1 4.6	1113.3 109.3 12,720,422 74.5 42.0 4.4
Adj. BVPS (Rs) Gross advances Credit to deposit (%) CASA ratio (%) Cost of deposits (%)	80.3 56.3 7,853,575 63.5 46.6 3.8	83.0 67.7 8,855,766 64.8 42.0 3.9	88.9 83.1 9,962,736 69.0 41.1 4.7	100.0 94.9 11,158,265 72.0 41.1 4.6	113.3 109.3
Adj. BVPS (Rs) Gross advances Credit to deposit (%) CASA ratio (%) Cost of deposits (%) Loans-to-Assets (%)	80.3 56.3 7,853,575 63.5 46.6 3.8 55.4	83.0 67.7 8,855,766 64.8 42.0 3.9 56.8	88.9 83.1 9,962,736 69.0 41.1 4.7 60.8	100.0 94.9 11,158,265 72.0 41.1 4.6 63.0	113.3 109.3 12,720,422 74.5 42.0 4.4 64.5

Source: Company, Emkay Research

Source: Company, Emkay Research

Asset Quality and Other Metrics										
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E					
Asset quality										
Gross NPLs	924,479.7	773,276.0	571,530.6	437,631.4	312,971.3					
Net NPLs	352,761.6	225,850.2	85,729.6	78,773.7	62,594.3					
GNPA ratio (%)	11.8	8.7	5.7	3.9	2.5					
NNPA ratio (%)	4.8	2.7	0.9	0.7	0.5					
Provision coverage (%)	61.8	70.8	85.0	82.0	80.0					
Gross slippages	247,436.7	160,289.2	89,664.6	133,899.2	178,085.9					
Gross slippage ratio (%)	3.2	1.8	0.9	1.2	1.4					
LLP ratio (%)	2.1	2.1	1.5	0.6	0.7					
NNPA to net worth (%)	37.7	23.1	8.2	6.3	4.4					
Capital adequacy										
Total CAR (%)	14.5	15.5	14.7	15.5	15.2					
Tier-1 (%)	11.7	12.7	12.0	13.0	12.9					
CET-1 (%)	10.6	11.4	10.9	12.0	12.0					
RWA-to-Total Assets (%)	45.7	45.1	48.0	49.0	50.0					
Miscellaneous										
Total income growth (%)	(6.0)	11.6	22.4	6.9	9.1					
Opex growth (%)	(0.3)	19.0	13.0	9.0	8.2					
Core PPOP growth (%)	(4.3)	32.8	2.8	1.9	11.1					
PPOP margin (%)	1.6	1.6	1.7	20.8	22.3					
PAT/PPOP (%)	16.7	11.1	30.6	51.3	57.7					
LLP-to-Core PPOP (%)	92.3	77.1	52.7	25.1	26.0					
Yield on advances (%)	7.3	7.6	8.7	8.4	8.1					
Cost of funds (%)	3.9	4.0	4.8	4.7	4.6					

Source: Company, Emkay Research

Valuations and Key Ratios Y/E Mar **FY22** FY23 FY24E FY25E FY26E P/E (x) 29.2 41.3 7.8 13.5 6.2 P/B (x) 1.2 1.1 1.1 0.9 0.8 P/ABV (x) 1.7 1.4 1.1 1.0 0.9 P/PPOP (x) 5.5 5.1 4.6 4.6 3.9 Dividend yield (%) 0.6 0.6 1.0 1.5 1.9 DuPont-RoE split (%) NII/avg assets 2.2 2.5 2.7 2.7 2.7 Other income 0.8 1.0 0.9 0.8 0.8 0.5 Fee income 0.5 0.5 0.4 0.5 Opex 1.6 1.7 1.8 1.8 1.8 PPOP 1.6 1.6 1.7 1.6 1.7 Core PPOP 1.7 1.5 1.5 1.4 1.6 Provisions 1.3 1.3 0.8 0.4 0.4 Tax expense 0.1 0.1 0.3 0.4 0.3 RoA (%) 0.3 0.2 0.5 0.8 1.0 Leverage ratio (x) 15.0 15.4 16.0 15.2 14.7 RoE (%) 4.0 2.8 8.1 12.7 14.3 **Quarterly data Q3FY23** Q4FY23 Q1FY24 **Q2FY24 Q3FY24** Rs mn, Y/E Mar NII 91,794 94,988 99,229 102,928 95,043 NIM (%) 3.2 3.2 3.1 3.1 3.2 PPOP 57,159 58,664 59,680 62,164 63,307 PAT 6,289 11,586 12,554 17,561 22,228 EPS (Rs) 0.57 1.05 1.59 2.02 1.14

Source: Company, Emkay Research

This report is intended for team emkay@whitemarquesolutions.com use and downloaded at 04/26/2024 02:13 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
30-Nov-23	78	78	Reduce	Anand Dama
27-Oct-23	73	78	Hold	Anand Dama
09-Mar-23	51	48	Hold	Anand Dama
16-Feb-23	51	48	Hold	Anand Dama
18-Nov-22	46	30	Sell	Anand Dama
30-May-22	32	28	Sell	Anand Dama
30-Oct-21	42	35	Sell	Anand Dama
04-Aug-21	39	33	Sell	Anand Dama
08-Jun-21	41	33	Sell	Anand Dama
09-Feb-21	39	29	Sell	Anand Dama

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Bloomberg, Company, Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 04/26/2024 02:13 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014, EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information. it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 04/26/2024 02:13 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGESL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in 1. the securities recommended in this report as of January 26, 2024
- GFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report 2. Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report З during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities 4. recommended in this report as of January 26, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the 5. subject company at the end of the month immediately preceding the January 26, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months. 6.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for
- investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.	
BUY	>15% upside	
ADD	5-15% upside	
REDUCE	5% upside to 15% downside	
SELL	<15% downside	

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkavglobal.com

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 04/26/2024 02:13 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject Company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates for the subject company in the past twelve months.